ロード中...
Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations
AML with RUNX1-RUNX1T1 fusion is a WHO entity with a favorable outcome following intensive chemotherapy. The absence of RUNX1-RUNX1T1 transcripts in remission defines complete molecular response and correlates with a superior survival. However, a significant proportion of patients still relapses and...
保存先:
| 出版年: | Hemasphere |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer Health
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6745937/ https://ncbi.nlm.nih.gov/pubmed/31723813 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000178 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|